Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation
Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Keaton B, Acquah SO, Im Lee Y (2022) · ASAIO Journal · n=0
Perfil del estudio
- Diseño
- systematic review and random-effects meta-analysis of 11 observational studies (Embase, Cochrane Central, MEDLINE)
- Tamaño de la muestra (n)
- —
- Intervención
- Bivalirudin anticoagulation in ECMO patients
- Comparador
- Heparin anticoagulation in ECMO patients
- Punto final primario
- Short-term mortality
- Resultado primario
- Bivalirudin associated with significantly lower short-term mortality (OR 0.71, 95% CI 0.55-0.92, p=0.01, I²=7%) compared with heparin in ECMO patients
- Duración del seguimiento
- Hospital discharge / short-term
- PMID
- 36194483
Hallazgos clave
- Mortality signal in favor of bivalirudin (OR 0.71, p=0.01)
- Low heterogeneity (I²=7%) supports robustness
- Adds quantitative mortality endpoint to ECMO anticoagulant literature
- Random-effects model used to account for clinical heterogeneity
- Calls for prospective RCT confirmation
Limitaciones
- All included studies observational
- Selection bias - bivalirudin often reserved for HIT or bleeding patients
- Variable anticoagulation monitoring strategies across studies
- Cannot establish causation
- Not applicable to whole-leech hirudotherapy
Implicaciones clínicas
Hasegawa 2022 contributes a positive mortality signal to the broader bivalirudin ECMO evidence base. For ASH, the meta-analysis demonstrates how the synthetic thrombin inhibitor pathway generates emerging mortality signals under retrospective synthesis, structurally separate from the K040187 device-leech US clinical practice. The mortality finding warrants RCT confirmation.
Estudios relacionados
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, Cannon CP (1995)
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)
Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps
Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)
Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024)